Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels

RVMD
Revolution Medicines, Inc. Common Stock
stock NASDAQ

Market Open
Aug 11, 2026 1:28:11 PM EDT
207.45USD+0.234%(+0.49)784,165
207.10Bid   207.68Ask   0.58Spread
Pre-market
Aug 11, 2026 8:53:30 AM EDT
208.36USD+0.676%(+1.40)298
After-hours
Aug 10, 2026 4:40:30 PM EDT
206.97USD+0.005%(+0.01)0
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 11, 2022
02:16PM EST  Revolution Medicines Reports Progress Across Pipeline Of Targeted Therapeutics For RAS-Addicted Cancers   Benzinga
02:15PM EST  RAS(ON) Inhibitor Pipeline Expands with Advancement of Two New Drug Candidates; Development-Stage Portfolio Covers RAS Drivers of Majority of RAS-Addicted Cancers   GlobeNewswire Inc
Jan 4, 2022
07:30AM EST  Revolution Medicines to Provide R&D Update, Including Expansion of   GlobeNewswire Inc
Nov 24, 2021
07:30AM EST  Revolution Medicines to Participate in 4th Annual Evercore ISI   GlobeNewswire Inc
Nov 12, 2021
06:21AM EST  HC Wainwright & Co. Maintains Buy on Revolution Medicines, Raises Price Target to $38   Benzinga
Nov 10, 2021
05:36PM EST  Revolution Medicines Q3 EPS $(0.72), Sales $1.10M Down From $12.66M YoY   Benzinga
04:09AM EST  Earnings Scheduled For November 10, 2021   Benzinga
Nov 8, 2021
04:05PM EST  Revolution Medicines to Participate in Stifel 2021 Virtual   GlobeNewswire Inc
Oct 11, 2021
04:06PM EDT  It's a Done Deal: 365 Cannabis Sold to Akerna   Benzinga
Sep 30, 2021
07:30AM EDT  Revolution Medicines to Present New Preclinical Data from RAS(ON)   GlobeNewswire Inc
Sep 23, 2021
04:59AM EDT  Stifel Initiates Coverage On Revolution Medicines with Hold Rating, Announces Price Target of $34   Benzinga
Sep 15, 2021
07:30AM EDT  Revolution Medicines to Participate in 3rd Annual RAS-Targeted   GlobeNewswire Inc
Sep 7, 2021
04:05PM EDT  Revolution Medicines to Present at H.C. Wainwright 23rd Annual   GlobeNewswire Inc
Aug 17, 2021
06:27AM EDT  HC Wainwright & Co. Maintains Buy on Revolution Medicines, Lowers Price Target to $31   Benzinga
Aug 13, 2021
07:43AM EDT  The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO   Benzinga
Aug 12, 2021
10:04AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For August 12, 2021   Benzinga
09:05AM EDT  Goldman Sachs Downgrades Revolution Medicines to Neutral, Lowers Price Target to $27   Benzinga
08:09AM EDT  The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma   Benzinga
04:41AM EDT  SVB Leerink Maintains Outperform on Revolution Medicines, Lowers Price Target to $38   Benzinga
Aug 11, 2021
05:04PM EDT  Revolution Medicines: Q2 Earnings Insights   Benzinga
04:15PM EDT  Revolution Medicines Q2 EPS $(0.60) Misses $(0.56) Estimate, Sales $8.70M Miss $9.38M Estimate   Benzinga
04:01PM EDT  Company Shows Continued Progress Demonstrating Differentiation of RAS(ON) Inhibitors, Targeting Additional RAS Variants and Progressing Assets Toward the Clinic   GlobeNewswire Inc
09:06AM EDT  Earnings Scheduled For August 11, 2021   Benzinga
08:14AM EDT  The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering   Benzinga
04:27AM EDT  Earnings Scheduled For August 11, 2021   Benzinga
Aug 9, 2021
11:07AM EDT  The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight   Benzinga
Aug 4, 2021
04:05PM EDT  Revolution Medicines to Report Financial Results for Second   GlobeNewswire Inc
Jun 24, 2021
04:06PM EDT  Revolution Medicines Announces Publication of Scientific Paper Describing Novel Class of Anti-Tumor Compounds Targeting mTORC1   Benzinga
04:05PM EDT  Revolution Medicines Announces Publication of Scientific Paper   GlobeNewswire Inc
Jun 10, 2021
07:30AM EDT  Revolution Medicines to Host Science Talk Webcast Highlighting   GlobeNewswire Inc
Jun 2, 2021
07:30AM EDT  Revolution Medicines to Participate in Goldman Sachs 42nd Annual   GlobeNewswire Inc
May 28, 2021
08:02AM EDT  The Daily Biotech Pulse: Biohaven, Bristol-Myers Squibb Snag FDA Approvals, Iterum UTI Drug Review On Track, Centessa Pharmaceuticals Debuts On Nasdaq   Benzinga
May 18, 2021
10:05AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For May 18, 2021   Benzinga
07:30AM EDT  Revolution Medicines to Participate in Cowen 2nd Annual Virtual   GlobeNewswire Inc
06:49AM EDT  Goldman Sachs Initiates Coverage On Revolution Medicines with Buy Rating, Announces Price Target of $49   Benzinga
May 11, 2021
07:49AM EDT  10 Biggest Price Target Changes For Tuesday   Benzinga
06:25AM EDT  SVB Leerink Maintains Outperform on Revolution Medicines, Lowers Price Target to $46   Benzinga
May 10, 2021
04:18PM EDT  Revolution Medicines Q1 EPS $(0.53) Up From $(0.74) YoY, Sales $10.13M Down From $11.55M YoY   Benzinga
04:05PM EDT  Multiple AACR Presentations Highlight Potential Advantages of RAS(ON) Inhibitors;Scientific Publication is First to Demonstrate Anti-Drug Resistance Features   GlobeNewswire Inc
May 3, 2021
07:05AM EDT  Revolution Medicines Highlights Slate of Diverse Board of   GlobeNewswire Inc
Apr 21, 2021
07:00AM EDT  First-in-Class Bi-steric mTORC1 Inhibitor Advances into Clinical Development   GlobeNewswire Inc
Mar 11, 2021
04:05PM EST  Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, today announced the company will make six presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2021 being held April 10-15, 2021 in a virtual format.   GlobeNewswire Inc
Mar 9, 2021
07:30AM EST  Revolution Medicines to Participate in Upcoming Investor Conferences   GlobeNewswire Inc
Mar 2, 2021
04:41PM EST  Revolution Medicines Files For Mixed Shelf Offering; Size Not Disclosed   Benzinga
04:24PM EST  Revolution Medicines Sees FY21 GAAP Net Loss $170M-$190M   Benzinga
04:18PM EST  Revolution Medicines Q3 EPS $(0.52) Misses $(0.38) Estimate, Sales $8.75M Down From $12.09M YoY   Benzinga
04:05PM EST  Advanced and Expanded Portfolio of RAS(ON) Inhibitors; Two Assets Entered IND-Enabling Development   GlobeNewswire Inc
Feb 18, 2021
07:30AM EST  Revolution Medicines to Participate in Digital RAS-Targeted Drug   GlobeNewswire Inc
Feb 8, 2021
04:01PM EST  Underwriters Full Exercise of Option Brings Gross Proceeds to $300 Million   GlobeNewswire Inc
Feb 5, 2021
07:44AM EST  The Daily Biotech Pulse: J&J Files For COVID-19 Vaccine Approval, Zimmer Biomet's Spin-Off, IPO Deluge Hits Street   Benzinga
Feb 4, 2021
07:54AM EST  Revolution Medicines Raises $260.9 Million In Upsized Offering   Benzinga
07:22AM EST  The Daily Biotech Pulse: Novartis COVID-19 Drug Readout, Merck And Roche Earnings, 3 IPOs   Benzinga
05:57AM EST  Revolution Medicines Priced Upsized 5.8M Share Public Offering of Common Stock @$45/Share   Benzinga
Feb 3, 2021
11:41PM EST  Revolution Medicines Announces Pricing Of Public Offering Of 5.8 Mln Common Shares At $45/Shr   RTTNews
11:30PM EST  Revolution Medicines Announces Pricing of Upsized $260.9 Million   GlobeNewswire Inc
Feb 1, 2021
04:09PM EST  Revolution Medicines 8-K Shows Co. Had Cash, Cash Equivalents, Marketable Securities As Of Dec. 31, 2020 $440.7M   Benzinga
04:01PM EST  Revolution Medicines Announces Proposed Public Offering of 4M Shares of Common Stock   Benzinga
04:01PM EST  Revolution Medicines, Inc. (Nasdaq: RVMD) today announced that it has commenced an underwritten public offering of 4,000,000 shares of common stock. All of the shares of common stock are being offered by Revolution Medicines. In addition, Revolution Medicines intends to grant the underwriters a 30-day option to purchase up to an additional 600,000 shares of common stock.   GlobeNewswire Inc
Jan 5, 2021
07:30AM EST  Revolution Medicines to Provide R&D Pipeline Update, Including   GlobeNewswire Inc
Dec 17, 2020
08:10AM EST  The Daily Biotech Pulse: MacroGenics Breast Cancer Drug Wins FDA Approval, Adcom Test Awaits Moderna, Virios To Make Wall Street Debut   Benzinga
Nov 12, 2020
03:45PM EST  Why Revolution Medicines Stock Is Trading Higher   Benzinga
07:37AM EST  Revolution Medicines Q3 EPS $(0.42) Up From $(6.08) YoY, Sales $12.66M Up From $12.51M YoY   Benzinga
07:30AM EST  Recommended Phase 2 Dose and Schedule Selected for Further Evaluation of RMC-4630 as Monotherapy and RMC-4630 plus Cobimetinib Combination   GlobeNewswire Inc
Oct 26, 2020
06:55AM EDT  HC Wainwright & Co. Maintains Buy on Revolution Medicines, Raises Price Target to $54   Benzinga
Oct 25, 2020
01:05PM EDT  Revolution Medicines Announced Saturday Progress and Expansion of Combination Strategy with RMC-4630 as Therapeutic Backbone for RAS-Addicted Cancers; Also Announced Collaboration with AstraZeneca   Benzinga
Oct 24, 2020
09:45AM EDT  Plenary Presentation at EORTC-NCI-AACR 32nd Symposium on Molecular Targets and Cancer Therapeutics Describes Encouraging Tolerability and Exposure Profilesfor RMC-4630 Combined with Cobimetinib and Early Evidence of Clinical Activity in RASmut Colorectal Cancers   GlobeNewswire Inc
Oct 12, 2020
07:33AM EDT  Revolution Medicines to Present Interim Data at ENA 2020 from Phase 1b/2 Clinical Trial Combining RMC-4630 with Cobimetinib for RAS-Addicted Solid Tumors   Benzinga
07:30AM EDT  Revolution Medicines to Present Interim Data at ENA 2020 from   GlobeNewswire Inc
Sep 16, 2020
09:04AM EDT  Revolution Medicines Reports Preclinical Tumor Regressions Induced By First-In-Class KRAS-G12D(ON) Inhibitors   Benzinga
09:00AM EDT  Presentation at 2nd Annual RAS-Targeted Drug Development Conference Highlights First Publicly Reported Data for Inhibitors of Notorious Cancer Protein KRASG12D(ON)   GlobeNewswire Inc
Sep 9, 2020
07:30AM EDT  Revolution Medicines to Present at the H.C. Wainwright 22nd Annual   GlobeNewswire Inc
Sep 8, 2020
07:30AM EDT  Revolution Medicines to Participate in 2nd Annual RAS-Targeted   GlobeNewswire Inc
Aug 11, 2020
10:01AM EDT  HC Wainwright & Co. Maintains Buy on Revolution Medicines, Lowers Price Target to $52   Benzinga
Aug 10, 2020
11:35AM EDT  SVB Leerink Maintains Outperform on Revolution Medicines, Lowers Price Target to $39   Benzinga
07:42AM EDT  Revolution Medicines Q2 EPS $(0.46) Up From $(4.85) YoY, Sales $10.03M Down From $12.28M YoY   Benzinga
07:42AM EDT  Interim RMC-4630 Data Support Benefit of Intermittent Dosing and Corroborate Clinical Activity Against Genetically-Defined Tumors   GlobeNewswire Inc
Jul 13, 2020
04:02PM EDT  Revolution Medicines Prices 6.9M Share Offering At $26/Share   Benzinga
04:01PM EDT  Revolution Medicines Announces Closing of Upsized Public Offering   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC